Nektar Therapeutics NKTR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -284.2%+12.9pp | -297.1%-92.6pp | -204.5%-31.6pp | -172.9%-12.1pp | -160.8%-32.6pp | |
| Returns | ||||||
| Return on invested capital | -35.4%+50.6pp | -86%-14.9pp | -71%+22.2pp | -93.2%-18.0pp | -75.2%-13.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.1× | 0.2×0.0× | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.2×+5.2× | 5×+0.7× | 4.2×+1.6× | 2.6×-0.6× | 3.2×-1.0× | |
| Per Share | ||||||
| Book value per share | $23.29+337% | $5.32+18.6% | $4.49+361% | -$1.72-276% | $0.98-77.9% | |
| Valuation | ||||||
| Market capitalization | $2.06B+140% | $860.04M-20.5% | $1.08B+257% | $303.35M+140% | $126.55M-26.2% | |
| Price / sales | 37.1×+21.5× | 15.6×-1.7× | 17.3×+13.2× | 4×+2.6× | 1.5×-0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Nektar Therapeutics (NKTR) runs a 100.0% gross margin and a -242.0% operating margin, with a -284.2% net margin.
- Where do Nektar Therapeutics's ratios come from?
- Every ratio is computed from Nektar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.